2017 American Society of Hematology Annual Meeting*

Download All
December 9-12, 2017; Atlanta, Georgia
Review expert perspectives on key findings in nonmalignant hematologic disorders presented at the 2017 ASH annual meeting.
Julie Kanter, MD
Gary Lyman, MD, MPH, FASCO, FRCP (Edin)
Keith R. McCrae, MD
Guy A. Young, MD

Nonmalignant Hematologic Disorders

Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.

Released: December 20, 2017

Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.

Released: December 15, 2017

At full cost, rivaroxaban increases total healthcare costs but lowers clinical event costs vs aspirin when given as extended anticoagulant therapy for VTE.

Released: December 12, 2017

In this post hoc analysis, platelet counts ≥ 50 x 109/L were reached without rescue therapy in 84% of patients with persistent ITP vs 88% with chronic ITP.

Released: December 13, 2017

In this subgroup analysis of a phase II study, high-dose crizanlizumab delayed sickle cell–related pain crises across all defined subgroups of patients with sickle cell disease.

Released: December 12, 2017

Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.

Released: December 13, 2017

Initiation of eltrombopag reduced mean number of transfusions and healthcare resource utilization rates vs before eltrombopag administration.

Released: December 14, 2017

Emicizumab prevented or reduced bleeding episodes requiring treatment and was well tolerated by this pediatric population.

Released: December 12, 2017

Preliminary analysis finds that pharmacokinetic parameters of SC emicizumab Q4W were promising and consistent with previous observations.

Released: December 11, 2017

In this Expert Analysis of key data from the Hematology 2017 annual meeting, Julie Kanter, MD; Gary Lyman, MD, MPH, FASCO, FRCP (Edin); Keith R. McCrae, MD; and Guy A. Young, MD, discuss the clinical applicability of new findings in nonmalignant hematologic disorders presented at the conference, including sickle cell disease, immune thrombocytopenia, hemophilia A, venous thromboembolism, and aplastic anemia.

Julie Kanter, MD Gary Lyman, MD, MPH, FASCO, FRCP (Edin) Keith R. McCrae, MD Guy A. Young, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 27, 2018 Expired: No longer available for credit

Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.

Released: December 14, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings